Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 3/2010

Open Access 01-06-2010 | Original Paper

Using Electronic Drug Monitor Feedback to Improve Adherence to Antiretroviral Therapy Among HIV-Positive Patients in China

Authors: Lora L. Sabin, Mary Bachman DeSilva, Davidson H. Hamer, Keyi Xu, Jianbo Zhang, Tao Li, Ira B. Wilson, Christopher J. Gill

Published in: AIDS and Behavior | Issue 3/2010

Login to get access

Abstract

Effective antiretroviral therapy (ART) requires excellent adherence. Little is known about how to improve ART adherence in many HIV/AIDS-affected countries, including China. We therefore assessed an adherence intervention among HIV-positive patients in southwestern China. Eighty subjects were enrolled and monitored for 6 months. Sixty-eight remaining subjects were randomized to intervention/control arms. In months 7–12, intervention subjects were counseled using EDM feedback; controls continued with standard of care. Among randomized subjects, mean adherence and CD4 count were 86.8 vs. 83.8% and 297 vs. 357 cells/μl in intervention vs. control subjects, respectively. At month 12, among 64 subjects who completed the trial, mean adherence had risen significantly among intervention subjects to 96.5% but remained unchanged in controls. Mean CD4 count rose by 90 cells/μl and declined by 9 cells/μl among intervention and control subjects, respectively. EDM feedback as a counseling tool appears promising for management of HIV and other chronic diseases.
Literature
1.
Bangsberg DR, Hecht FM, Charlebois ED, Zolopa AR, Holodniy M, Sheiner L, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357–66.CrossRefPubMed
2.
Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15(16):2109–17.CrossRefPubMed
3.
Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O’Shaughnessy MV, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS. 2002;16(7):1051–8.CrossRefPubMed
4.
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133(1):21–30.PubMed
5.
Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis. 2006;43(7):939–41.CrossRefPubMed
6.
Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, Scarcella P, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral-treated patients in Sub-Saharan African sites with comprehensive monitoring availability. Clin Infect Dis. 2008;48:115–22.CrossRef
7.
Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load. A meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S23–35.PubMed
8.
Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Munoz A. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS. 2001;15(3):347–55.CrossRefPubMed
9.
Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D. Long-term impact of highly active antiretroviral therapy on HIV-related health care costs. J Acquir Immune Defic Syndr. 2001;27(1):14–9.PubMed
10.
Sendi PP, Bucher HC, Harr T, Craig BA, Schwietert M, Pfluger D, et al. Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV cohort study. AIDS. 1999;13(9):1115–22.CrossRefPubMed
11.
Valenti WM. Treatment adherence improves outcomes and manages costs. AIDS Read. 2001;11(2):77–80.PubMed
12.
Kozal MJ, Hullsiek KH, Macarthur RD, Berg-Wolf M, Peng G, Xiang Y, et al. The incidence of HIV drug resistance and its impact on progression of HIV disease among antiretroviral-naive participants started on three different antiretroviral therapy strategies. HIV Clin Trials. 2007;8(6):357–70.CrossRefPubMed
13.
Hogg RS, Bangsberg DR, Lima VD, Alexander C, Bonner S, Yip B, et al. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. PLoS Med. 2006;3(9):e356.CrossRefPubMed
14.
Colson P, Ravaux I, Yahi N, Tourres C, Gallais H, Tamalet C. Transmission of HIV-1 variants resistant to the three classes of antiretroviral agents: implications for HIV therapy in primary infection. AIDS. 2002;16(3):507–9.CrossRefPubMed
15.
Siegrist CA, Yerly S, Kaiser L, Wyler CA, Perrin L. Mother to child transmission of zidovudine-resistant HIV-1. Lancet. 1994;344(8939–8940):1771–2.CrossRefPubMed
16.
Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr. 2006;41(3):285–97.CrossRefPubMed
17.
DiIorio C, Resnicow K, McDonnell M, Soet J, McCarty F, Yeager K. Using motivational interviewing to promote adherence to antiretroviral medications: a pilot study. J Assoc Nurses AIDS Care. 2003;14(2):52–62.CrossRefPubMed
18.
Goujard C, Bernard N, Sohier N, Peyramond D, Lancon F, Chwalow J, et al. Impact of a patient education program on adherence to HIV medication: a randomized clinical trial. J Acquir Immune Defic Syndr. 2003;34(2):191–4.CrossRefPubMed
19.
Parsons JT, Golub SA, Rosof E, Holder C. Motivational interviewing and cognitive-behavioral intervention to improve HIV medication adherence among hazardous drinkers: a randomized controlled trial. J Acquir Immune Defic Syndr. 2007;46(4):443–50.CrossRefPubMed
20.
Safren SA, Otto MW, Worth JL, Salomon E, Johnson W, Mayer K, et al. Two strategies to increase adherence to HIV antiretroviral medication: life-steps and medication monitoring. Behav Res Ther. 2001;39(10):1151–62.CrossRefPubMed
21.
Bangsberg DR. Monitoring adherence to HIV antiretroviral therapy in routine clinical practice: the past, the present, and the future. AIDS Behav. 2006;10(3):249–51.CrossRefPubMed
22.
Bangsberg DR. Preventing HIV antiretroviral resistance through better monitoring of treatment adherence. J Infect Dis. 2008;197(Suppl 3):S272–8.CrossRefPubMed
23.
Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–23.CrossRefPubMed
24.
Smith SR, Rublein JC, Marcus C, Brock TP, Chesney MA. A medication self-management program to improve adherence to HIV therapy regimens. Patient Educ Couns. 2003;50(2):187–99.PubMed
25.
Rosen MI, Dieckhaus K, McMahon TJ, Valdes B, Petry NM, Cramer J, et al. Improved adherence with contingency management. AIDS Patient Care STDS. 2007;21(1):30–40.CrossRefPubMed
26.
World Health Organization. The world health report—working together for health. Geneva: World Health Organization; 2006.
27.
State Council AIDS Working Committee Office & UN Theme Group on AIDS in China. A joint assessment of HIV/AIDS prevention, treatment and care in China (2007). Beijing: December 1, 2007.
28.
UNAIDS. Report on the global AIDS epidemic 08. Mexico City: Joint United Nations Programme on HIV/AIDS; August 2008.
29.
Wu Z, Rou K, Detels R. Prevalence of HIV infection among former commercial plasma donors in rural eastern China. Health Policy Plan. 2001;16(1):41–6.CrossRefPubMed
30.
Ministry of Health of China, UNAIDS, WHO. 2005 update on the HIV/AIDS epidemic and response in China. Beijing: Ministry of Health; 2006.
31.
Yan J, Zheng X, Zhang X, et al. The survey of prevalence of HIV infection among paid blood donors in one county in China. Zhonghua Liu Xing Bing Xue Za Zhi [Chinese Journal of Infectious Diseases]. 2000;21(1):10–3.
32.
He N, Detels R. The HIV epidemic in China: history, response, and challenge. Cell Res. 2005;15(11–12):825–32.CrossRefPubMed
33.
Wu Z, Sullivan SG, Wang Y, Rotheram-Borus MJ, Detels R. Evolution of China’s response to HIV/AIDS. Lancet. 2007;369(9562):679–90.CrossRefPubMed
34.
Zhang F, Hsu M, Yu L, Wen Y, Two J, Zhang R. Initiation of the national ARV therapy program in rural China. Beijing: July 2004.
35.
Zhang F, Hsu M, Yu L, Wen Y, Pan J. Initiation of the national free antiretroviral therapy program in rural China. In: Kaufman J, Kleinman A, Saich T, editors. AIDS and social policy in China. Cambridge, MA: Harvard University Asia Center; 2006. p. 96–104.
36.
Starks H, Simoni J, Zhao H, Huang B, Fredriksen-Goldsen K, Pearson C, et al. Conceptualizing antiretroviral adherence in Beijing, China. AIDS Care. 2008;20(6):607–14.CrossRefPubMed
37.
Sabin LL, Desilva MB, Hamer DH, Keyi X, Yue Y, Wen F, et al. Barriers to adherence to antiretroviral medications among patients living with HIV in southern China: a qualitative study. AIDS Care. 2008;20(10):1242–50.CrossRefPubMed
38.
Wang H, He G, Li X, Yang A, Chen X, Fennie KP, et al. Self-reported adherence to antiretroviral treatment among HIV-infected people in Central China. AIDS Patient Care STDS. 2008;22(1):71–80.CrossRefPubMed
39.
Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006;25(4):462–73.CrossRefPubMed
40.
Gill CJ, Sabin LL, Hamer DH, Xu K, Zhang J, Li T, Wu W-J, Wilson IB, Bachman DeSilva M. Importance of dose timing to achieving undetectable viral loads. AIDS Behav. 2009; Published online: April 8, 2009.
41.
Xiao Y, Kristensen S, Sun J, Lu L, Vermund SH. Expansion of HIV/AIDS in China: lessons from Yunnan Province. Soc Sci Med. 2007;64(3):665–75.CrossRefPubMed
42.
Remien RH, Stirratt MJ, Dolezal C, Dognin JS, Wagner GJ, Carballo-Dieguez A, et al. Couple-focused support to improve HIV medication adherence: a randomized controlled trial. AIDS. 2005;19(8):807–14.CrossRefPubMed
43.
Margolin A, Avants SK, Warburton LA, Hawkins KA, Shi J. A randomized clinical trial of a manual-guided risk reduction intervention for HIV-positive injection drug users. Health Psychol. 2003;22(2):223–8.CrossRefPubMed
Metadata
Title
Using Electronic Drug Monitor Feedback to Improve Adherence to Antiretroviral Therapy Among HIV-Positive Patients in China
Authors
Lora L. Sabin
Mary Bachman DeSilva
Davidson H. Hamer
Keyi Xu
Jianbo Zhang
Tao Li
Ira B. Wilson
Christopher J. Gill
Publication date
01-06-2010
Publisher
Springer US
Published in
AIDS and Behavior / Issue 3/2010
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-009-9615-1

Other articles of this Issue 3/2010

AIDS and Behavior 3/2010 Go to the issue

Original Paper

A Randomized Controlled Trial of an HIV Prevention Intervention for Street-Based Female Sex Workers in Yerevan, Armenia: Preliminary Evidence of Efficacy

Original Paper

A Randomized Trial to Evaluate the Efficacy of a Computer-Tailored Intervention to Promote Safer Injection Practices Among Drug Users

Original Paper

Comparing Couples’ and Individual Voluntary Counseling and Testing for HIV at Antenatal Clinics in Tanzania: A Randomized Trial

Original Paper

Barriers to Pharmacy-Based Syringe Purchase Among Injection Drug Users in Tijuana, Mexico: A Mixed Methods Study

Original Paper

Provider-related Barriers to Rapid HIV Testing in U.S. Urban Non-profit Community Clinics, Community-based Organizations (CBOs) and Hospitals

Original Paper

Patterns of Self-reported Behaviour Change Associated with Receiving Voluntary Counselling and Testing in a Longitudinal Study from Manicaland, Zimbabwe
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits